IN2014CN04406A - - Google Patents
Info
- Publication number
- IN2014CN04406A IN2014CN04406A IN4406CHN2014A IN2014CN04406A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A IN 4406CHN2014 A IN4406CHN2014 A IN 4406CHN2014A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A
- Authority
- IN
- India
- Prior art keywords
- oxadiazol
- fluoro
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 abstract 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001992 poloxamer 407 Polymers 0.000 abstract 1
- 229940044476 poloxamer 407 Drugs 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 239000008371 vanilla flavor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78733306P | 2006-03-30 | 2006-03-30 | |
| US81308506P | 2006-06-12 | 2006-06-12 | |
| PCT/US2007/008268 WO2007117438A2 (en) | 2006-03-30 | 2007-03-29 | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04406A true IN2014CN04406A (es) | 2015-09-04 |
Family
ID=38480572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4406CHN2014 IN2014CN04406A (es) | 2006-03-30 | 2007-03-29 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9289398B2 (es) |
| EP (2) | EP2007365A2 (es) |
| JP (2) | JP5367563B2 (es) |
| CN (1) | CN101505739A (es) |
| AU (1) | AU2007235524B2 (es) |
| BR (1) | BRPI0710213A2 (es) |
| CA (1) | CA2647903C (es) |
| IL (2) | IL194454A (es) |
| IN (1) | IN2014CN04406A (es) |
| MX (1) | MX2008012515A (es) |
| NO (1) | NO20084488L (es) |
| NZ (2) | NZ596965A (es) |
| RU (1) | RU2462246C2 (es) |
| SG (1) | SG170819A1 (es) |
| WO (1) | WO2007117438A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2770035T3 (es) | 2003-04-11 | 2020-06-30 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| EP2251437B1 (en) * | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
| US9604961B2 (en) | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN103074346A (zh) * | 2013-01-22 | 2013-05-01 | 山西大学 | 一种用于促通读药物筛选的有限细胞株的建立方法 |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2942147C (en) * | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| DK3925607T3 (da) * | 2014-04-15 | 2023-08-21 | Vertex Pharma | Farmaceutiske sammensætninger til behandlingen af cystisk fibrosetransmembrankonduktansregulator-medierede sygdomme |
| JP2016155900A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社フジミインコーポレーテッド | 研磨用組成物、研磨方法及び硬脆材料基板の製造方法 |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| WO2017112954A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| CN107916252B (zh) * | 2017-11-17 | 2021-01-22 | 首都儿科研究所 | 一株用于验证脊肌萎缩症的永生淋巴细胞株 |
| US12458629B2 (en) | 2019-04-10 | 2025-11-04 | Ptc Therapeutics, Inc. | Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL291628A (es) * | 1962-04-17 | |||
| US3325446A (en) * | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
| US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
| US4016170A (en) * | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
| US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4268299A (en) * | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| EP0036711B1 (en) * | 1980-03-22 | 1985-12-04 | Fbc Limited | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
| DE3148449C1 (de) | 1981-12-08 | 1983-06-01 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Verfahren zur Verringerung von Registerfehlern und Druckmaschine zur Durchfuehrung des Verfahrens |
| GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
| US5037052A (en) | 1989-04-21 | 1991-08-06 | Crisp Joe E | Clamp assembly system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5036761A (en) | 1989-11-20 | 1991-08-06 | Wingo Patrick Y | Forced flow press dampening apparatus |
| US4984286A (en) | 1989-12-12 | 1991-01-08 | Analogic Corporation | Spatial filter system |
| US5036762A (en) | 1990-06-12 | 1991-08-06 | Sarda Jean Lucien | Apparatus for supplying offset printing presses with a cooled damping solution |
| AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
| JPH06510524A (ja) | 1991-05-14 | 1994-11-24 | ユニバーシティ オブ コネチカット | 免疫原性タンパク質をコードする遺伝子の標的への配達 |
| DE69231385T2 (de) | 1991-06-05 | 2001-04-12 | The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| PT671923E (pt) | 1992-10-09 | 2001-10-30 | Advanced Tissue Sciences Inc | Celulas de reserva do figado |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
| US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| RU2164419C2 (ru) * | 1994-03-18 | 2001-03-27 | Мириад Дженетикс, Инк. | Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts |
| TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
| CZ66498A3 (cs) | 1995-09-07 | 1998-07-15 | Novartis Ag | Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
| US6034106A (en) * | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
| DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| CA2284732C (en) * | 1997-04-07 | 2008-06-17 | Georgetown University | Analogs of cocaine |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| KR100568658B1 (ko) * | 1998-02-26 | 2006-04-07 | 아벤티스 파마슈티칼스 인크 | 6,9-이치환 2-[트랜스-(4-아미노시클로헥실)아미노]퓨린 |
| NZ507696A (en) | 1998-04-23 | 2003-10-31 | Cortech Inc | Triazole, oxadiazole and thiadiazole derivatives useful as cysteine protease inhibitors |
| DE69914931T2 (de) | 1998-10-09 | 2004-12-16 | Janssen Pharmaceutica N.V. | 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung |
| AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
| TR200101869T2 (tr) * | 1998-12-23 | 2002-01-21 | Smithkline Beecham Corporation | Proteaz İnhibitörleri. |
| EP1157274A1 (en) * | 1999-03-02 | 2001-11-28 | The University of Dundee | Methods of determining altered ndpk functions |
| WO2000058278A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives d'acides amines $g(b) |
| AU3196300A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Carbocyclic sulfonamide derivatives |
| AU3196100A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
| PL352367A1 (en) | 1999-05-17 | 2003-08-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| EP1268494A1 (en) * | 2000-03-22 | 2003-01-02 | Merck Frosst Canada & Co. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| AU2001257413B2 (en) | 2000-05-22 | 2007-01-18 | Aventisub Llc | Arylmethylamine derivatives for use as tryptase inhibitors |
| US7366402B2 (en) | 2000-06-02 | 2008-04-29 | Lg Electronics Inc. | Method and apparatus of recording a high definition digital television broadcast signal |
| JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| US7115612B2 (en) | 2001-04-19 | 2006-10-03 | Bayer Aktiengesellschaft | Arylsulfonamides as antiviral agents |
| US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2003247610A1 (en) | 2002-06-21 | 2004-01-06 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| WO2004010106A2 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| AU2003254157A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US7291603B2 (en) | 2002-07-24 | 2007-11-06 | Ptc Therapeutics, Inc. | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
| US7074809B2 (en) | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| AR041508A1 (es) | 2002-08-09 | 2005-05-18 | Astra Ab | Compuestos con actividad en los receptores de glutamato metabotropicos |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7555125B2 (en) | 2003-08-14 | 2009-06-30 | Broadcom Corporation | Systems and methods for generation of time-dependent control signals for video signals |
| ES2770035T3 (es) * | 2003-04-11 | 2020-06-30 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| JP3852934B2 (ja) | 2003-05-20 | 2006-12-06 | 株式会社バンダイナムコゲームス | 画像処理システム、プログラム及び情報記憶媒体 |
| US20050037052A1 (en) | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
| KR100565056B1 (ko) | 2003-08-14 | 2006-03-30 | 삼성전자주식회사 | Ａｖ 데이터를 ｅｎａｖ 모드로 재생하는 방법, 그 장치및 그 정보저장매체 |
| WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US20080207538A1 (en) | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
| DE102004013599A1 (de) * | 2004-03-19 | 2005-10-06 | Robert Bosch Gmbh | Ansteuerschaltung zum Ansteuern einer leistungselektronischen Schaltung sowie Verfahren hierzu |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| CA2603402C (en) | 2005-04-08 | 2017-10-31 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| AU2007292915B2 (en) | 2006-09-08 | 2012-07-26 | Ptc Therapeutics, Inc. | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
| US8101641B2 (en) * | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
| WO2008039431A2 (en) * | 2006-09-25 | 2008-04-03 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| CA2675518C (en) | 2006-10-12 | 2017-11-14 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
-
2007
- 2007-03-29 WO PCT/US2007/008268 patent/WO2007117438A2/en not_active Ceased
- 2007-03-29 NZ NZ596965A patent/NZ596965A/xx not_active IP Right Cessation
- 2007-03-29 NZ NZ571899A patent/NZ571899A/en not_active IP Right Cessation
- 2007-03-29 RU RU2008142957/15A patent/RU2462246C2/ru not_active IP Right Cessation
- 2007-03-29 EP EP07754745A patent/EP2007365A2/en not_active Withdrawn
- 2007-03-29 IN IN4406CHN2014 patent/IN2014CN04406A/en unknown
- 2007-03-29 MX MX2008012515A patent/MX2008012515A/es active IP Right Grant
- 2007-03-29 US US12/294,952 patent/US9289398B2/en not_active Expired - Fee Related
- 2007-03-29 BR BRPI0710213-5A patent/BRPI0710213A2/pt not_active IP Right Cessation
- 2007-03-29 AU AU2007235524A patent/AU2007235524B2/en not_active Ceased
- 2007-03-29 EP EP11152243A patent/EP2387995A1/en not_active Withdrawn
- 2007-03-29 CA CA2647903A patent/CA2647903C/en not_active Expired - Fee Related
- 2007-03-29 JP JP2009503082A patent/JP5367563B2/ja not_active Expired - Fee Related
- 2007-03-29 SG SG201102327-2A patent/SG170819A1/en unknown
- 2007-03-29 CN CNA2007800201278A patent/CN101505739A/zh active Pending
-
2008
- 2008-09-28 IL IL194454A patent/IL194454A/en not_active IP Right Cessation
- 2008-10-24 NO NO20084488A patent/NO20084488L/no not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222557A patent/IL222557A/en active IP Right Grant
-
2013
- 2013-06-25 JP JP2013133071A patent/JP5798154B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/044,225 patent/US20160199357A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5367563B2 (ja) | 2013-12-11 |
| JP5798154B2 (ja) | 2015-10-21 |
| AU2007235524B2 (en) | 2013-09-12 |
| IL194454A0 (en) | 2009-08-03 |
| JP2009532368A (ja) | 2009-09-10 |
| WO2007117438A3 (en) | 2008-10-23 |
| JP2013234189A (ja) | 2013-11-21 |
| AU2007235524A1 (en) | 2007-10-18 |
| NZ596965A (en) | 2013-06-28 |
| NZ571899A (en) | 2012-07-27 |
| IL194454A (en) | 2013-01-31 |
| IL222557A (en) | 2016-09-29 |
| CA2647903A1 (en) | 2007-10-18 |
| US9289398B2 (en) | 2016-03-22 |
| BRPI0710213A2 (pt) | 2011-04-12 |
| CA2647903C (en) | 2016-12-13 |
| US20110046136A1 (en) | 2011-02-24 |
| EP2007365A2 (en) | 2008-12-31 |
| WO2007117438A2 (en) | 2007-10-18 |
| EP2387995A1 (en) | 2011-11-23 |
| MX2008012515A (es) | 2008-11-19 |
| SG170819A1 (en) | 2011-05-30 |
| RU2462246C2 (ru) | 2012-09-27 |
| IL222557A0 (en) | 2012-12-31 |
| CN101505739A (zh) | 2009-08-12 |
| NO20084488L (no) | 2008-12-19 |
| US20160199357A1 (en) | 2016-07-14 |
| RU2008142957A (ru) | 2010-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04406A (es) | ||
| PE20160947A1 (es) | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico | |
| US20120245186A1 (en) | Combination cancer therapy with hsp90 inhibitory compounds | |
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| HRP20200753T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
| JP2003528918A5 (es) | ||
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| WO2007048219A3 (en) | Sustained drug release composition | |
| IL231890A0 (en) | 7,3-diamino-10h-phenothiazine salts and their use | |
| JP2006520778A5 (es) | ||
| JP2007039461A5 (es) | ||
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| KR20030045035A (ko) | 시클로옥시게나제-2 억제제의 경구 고속-용해 제제 | |
| JP2005530787A5 (es) | ||
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| KR20220087443A (ko) | 셀렉시파그를 포함하는 약제학적 조성물 | |
| TNSN08447A1 (en) | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof | |
| CA2748409C (en) | Pharmaceutical formulations of olmesartan | |
| CA3006192A1 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
| WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
| ES2437916T3 (es) | Composición de raloxifeno | |
| JP2015504878A (ja) | 錠剤及び有核剤 |